close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Health Panel

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Nicole Lamanna

location-icon

New York, NY

LOCATION OF PRACTICE
Columbia University Herbert Irving Comprehensive Cancer Center
MEDICAL Specialty:

Chronic Lymphocytic Leukemia (cll)



NPI Number
1164493102
ABOUT

Nicole Lamanna, MD an Associate Clinical Professor of Medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division. Her research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia.

Dr. Nicole Lamanna profile image

Published Articles

Treatment-emergent coagulopathy during azacitidine/venetoclax induction in AML.- 2026 May
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.- 2025 Dec
Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis.- 2025 Nov
Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.- 2025 Dec
Predicting Mechanosensitive T Cell Expansion from Cell Spreading.- 2025 Nov
Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC).- 2025
Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.- 2025 Jun 24
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.- 2025 Jun 5
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.- 2025 Apr 22
SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia.- 2025 Jun

Clinical Trials

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

My Patient Resources

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider